NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Business Wire
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo in Vancouver, Canada, November 19-23 (booth #830). The research demonstrates how ctDNA and next-generation sequencing (NGS) can drive more personalized and accurate treatment options for cancer patients.“Our presence at AMP 2024 underscores NeoGenomics’ dedication to advancing cancer care through ongoing research in precision medicine,” said Warren Stone, CCO of NeoGenomics. “By continuing to improve our methods and technologies, we aim to enhance outcomes and set new standards for oncology testing.”NeoGenomics’ presentations include:A Solid Tumor Gene Fusion Next-Generation Sequencing Assay on the G4 Sequencing PlatformAbstract #1874602: Friday, November 22 | 9:15-10:15 a.m. PSTThe study highlights the G4 platform as a reliable and efficient alternative for clinical a
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment [Yahoo! Finance]Yahoo! Finance
- Felicia Williams Joins NeoGenomics Board of Directors [Yahoo! Finance]Yahoo! Finance
- Felicia Williams Joins NeoGenomics Board of DirectorsBusiness Wire
- NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceBusiness Wire
- NeoGenomics, Inc. (NASDAQ: NEO) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.MarketBeat
NEO
Earnings
- 11/5/24 - Beat
NEO
Sec Filings
- 11/19/24 - Form 4
- 11/15/24 - Form 144
- 11/14/24 - Form SC
- NEO's page on the SEC website